8月21日，1药网(YI)盘中上涨2.43%，截至00:24，报7.17美元/股，成交2.82万美元，总市值6214.55万美 元。 1药网旗下拥有:B2C医药平台"1药网"、互联网医院"1诊",B2B医药平台"1药城",通过创新的S2B2C的模 式,全面实现B端和C端、线上和线下、自营和平台、医+药+保险的融合发展。2018年,1药网成功登陆美 国纳斯达克,股票代码"YI",成为中国互联网医药健康赴美上市第一股。 大事提醒： 本文源自：金融界 9月4日，1药网将披露2025财年中报（数据来源于纳斯达克官网，预计披露日期为美国当地时间，实际 披露日期以公司公告为准）。 作者：行情君 资料显示，1药网公司是111集团的境外控股公司。1药网由于刚和刘峻岭于2010年创建,是中国互联网医 药健康的领军企业,致力于用数字科技将患者和药品及医疗服务有机连接,打造中国最大的医药健康平 台。 财务数据显示，截至2025年03月31日，1药网收入总额35.29亿人民币，同比增长0.02%；归母净利 润-1764.9万人民币，同比减少28.12%。 1药网基于在互联网科技、智能供应链、全渠道药品商业化、云服务方面建立的优势,与 ...

8月19日，1药网(YI)盘中上涨2.96%，截至02:41，报6.95美元/股，成交3.28万美元，总市值6023.87万美 元。 财务数据显示，截至2025年03月31日，1药网收入总额35.29亿人民币，同比增长0.02%；归母净利 润-1764.9万人民币，同比减少28.12%。 大事提醒： 9月4日，1药网将披露2025财年中报（数据来源于纳斯达克官网，预计披露日期为美国当地时间，实际 披露日期以公司公告为准）。 资料显示，1药网公司是111集团的境外控股公司。1药网由于刚和刘峻岭于2010年创建,是中国互联网医 药健康的领军企业,致力于用数字科技将患者和药品及医疗服务有机连接,打造中国最大的医药健康平 台。 1药网基于在互联网科技、智能供应链、全渠道药品商业化、云服务方面建立的优势,与药企、药品流通 商、保险企业等合作伙伴共建供应链服务平台,为B端的药店、医生赋能,从而更好地服务用户(S2B2C)。 1药网通过数字化手段重构医药健康的产业价值链,让需求和供给实现更高效的匹配,为中国大众的就医买 药提供完整的解决方案以及实惠和方便。 1药网旗下拥有:B2C医药平台"1药网"、互联网医院"1诊",B2 ...

Core Viewpoint - 1药网 (YI) is a leading player in China's internet healthcare sector, focusing on connecting patients with pharmaceuticals and medical services through digital technology, aiming to create the largest healthcare platform in China [2]. Financial Performance - As of March 31, 2025, 1药网 reported total revenue of 3.529 billion RMB, reflecting a year-on-year growth of 0.02% [1]. - The company's net profit attributable to shareholders was -17.649 million RMB, a decrease of 28.12% year-on-year [1]. Upcoming Events - 1药网 is scheduled to disclose its mid-year report for the fiscal year 2025 on September 4, 2024, with the actual disclosure date subject to company announcements [2]. Company Overview - 1药网, established in 2010 by Liu Junling, is a subsidiary of 111 Group and has become a leader in the Chinese internet healthcare industry [2]. - The company leverages its strengths in internet technology, smart supply chains, omnichannel commercialization of pharmaceuticals, and cloud services to build a supply chain service platform in collaboration with pharmaceutical companies, distributors, and insurance firms [2]. - 1药网 operates various platforms, including the B2C pharmaceutical platform "1药网," the internet hospital "1诊," and the B2B pharmaceutical platform "1药城," utilizing an innovative S2B2C model to integrate B-end and C-end services [2]. - In 2018, 1药网 successfully listed on NASDAQ under the ticker "YI," becoming the first Chinese internet healthcare company to go public in the U.S. [2].

Industry Transformation - The personal care industry in China is projected to exceed 650 billion yuan in market size by 2024, with a compound annual growth rate of 6.8% [1] - Three structural transformations are occurring: the rise of consumer sovereignty, supply chain efficiency bottlenecks, and the shift from a "channel-centric" to a "user-centric" paradigm [1] - The S2B2C model is emerging as a key solution to industry challenges, enhancing inventory turnover by 40%, increasing customer repurchase rates by 25%, and improving marketing ROI by over three times [1] S2B2C Model Core Architecture - The platform technology backbone supports full-link digitalization, integrating over 20 data sources to create a comprehensive data model [4] - AI capabilities enhance user experience, with a 35% increase in new product recommendation conversion rates through user profiling [4] - Demand forecasting using advanced models achieves an error rate of less than 8% [4] Supply Chain Collaboration Network - The S2B2C model enables a flexible production system and green logistics, enhancing supply chain visibility from raw material procurement to product delivery [7] - The implementation of VMI (Vendor Managed Inventory) improves safety stock calculation accuracy to 98% [7] - The introduction of real-time inventory synchronization between online and offline stores boosts average transaction value by 28% [7] Digital Solutions in the Personal Care Industry - Intelligent supply chain management leverages consumer demand data to drive R&D, with a new product sales exceeding 30 million yuan in the first month [8] - The full-channel marketing platform integrates various marketing tools, reducing video production costs by 70% [8] - Data-driven financial services provide dynamic credit for channel partners, with a cumulative loan issuance exceeding 30 billion yuan [8] Benchmark Case Study - A leading international personal care company faced challenges such as channel fragmentation and data silos, which were addressed through the S2B2C platform [8] - The implementation of a microservices architecture supports high concurrency and system availability [8] - The new model improved order processing accuracy to 0.02% and increased market share by 2.5 percentage points [8] Future Trends - The integration of AIGC applications enhances content production efficiency by tenfold [11] - Sustainable practices are being adopted, with packaging recovery rates reaching 30% [11] - Global expansion efforts include cross-border collaboration, with overseas orders accounting for 30% of total transactions [11] Conclusion - The S2B2C model is pivotal in transitioning the personal care industry from scale competition to value competition, emphasizing the importance of digital transformation and ecosystem collaboration [14]

Core Viewpoint - 1药网 (YI) has experienced a stock price increase of 5.02%, with a current share price of $7.278 and a total market capitalization of $63.08 million. Financial data indicates a total revenue of 14.401 billion RMB for the year ending December 31, 2024, representing a year-on-year decrease of 3.66%, while the net profit attributable to shareholders is -64.743 million RMB, showing a significant year-on-year increase of 83.51% [1][2]. Group 1 - 1药网 is a leading player in China's internet healthcare sector, founded in 2010 by Liu Junling, and aims to connect patients with pharmaceuticals and medical services through digital technology [2]. - The company operates a supply chain service platform in collaboration with pharmaceutical companies, distributors, and insurance firms, empowering B-end pharmacies and doctors to better serve users through an S2B2C model [2]. - 1药网 has restructured the pharmaceutical health industry's value chain using digital means, providing efficient matching of supply and demand, and offering comprehensive solutions for the public's medical and pharmaceutical needs [2]. Group 2 - The company owns several platforms, including the B2C pharmaceutical platform "1药网," the internet hospital "1诊," and the B2B pharmaceutical platform "1药城," achieving integration across B-end and C-end, online and offline, and self-operated and platform models [2]. - 1药网 successfully went public on NASDAQ in 2018 under the ticker "YI," becoming the first Chinese internet healthcare company to list in the United States [2].

Industry Overview - The baking industry in China is undergoing rapid transformation, with a variety of products emerging and consumer preferences shifting continuously. The market size for baked goods reached 561.42 billion yuan in 2023, growing by 9.2% year-on-year, and is expected to reach 859.56 billion yuan by 2029 [1] - The industry remains fragmented, with the top nine listed companies accounting for less than 6% of the market share as of 2022, indicating significant growth potential [1] Company Profile: 如慕令 - 如慕令, founded in late 2024, focuses on reinterpreting mousse cakes within a Chinese cultural context, integrating elements from traditional poetry and architecture into its designs, appealing to local consumer sentiments [5][9] - The brand targets younger consumers who view cakes as emotional products, emphasizing the importance of aesthetic appeal and cultural significance in their offerings [5][8] Product Strategy - 如慕令's cakes are designed with cultural symbols that convey specific meanings, such as "prosperity" and "peace," making them more relatable and meaningful to consumers [8][9] - The company emphasizes health by offering "0-calorie" options using sugar substitutes like erythritol, catering to health-conscious consumers who seek both taste and lower calorie intake [9] Business Model Innovation - The company utilizes a "cold chain" logistics model, allowing for standardized production in a central kitchen and consistent quality across locations, which is a departure from traditional baking methods that rely heavily on skilled labor [10][11] - 如慕令 adopts a "S2B2C" model, partnering with local bakeries to distribute its products, thus creating a network of small stores that can offer standardized cakes without extensive training or investment [11][12] Market Potential and Growth Plans - The cold baking market in China has significant growth potential, with only 10% penetration as of 2020, compared to higher rates in Japan and North America [10] - 如慕令 plans to expand rapidly, aiming to open 100 stores within two years and achieve monthly revenues exceeding 8 million yuan, with a current goal of raising 2.5 million yuan in angel funding [13]